Comparison of lipid amphotericin B preparations in treating murine zygomycosis.
We compared the efficacies of liposomal amphotericin B (LAmB) and an amphotericin B lipid complex (ABLC) in diabetic ketoacidotic (DKA) or neutropenic mice with disseminated zygomycosis. ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models.
Ibrahim
Ashraf S
AS
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California--Los Angeles Medical Center, Torrance, CA 90502, USA. ibrahim@labiomed.org
Gebremariam
Teclegiorgis
T
Husseiny
Mohamed I
MI
Stevens
David A
DA
Fu
Yue
Y
Edwards
John E
JE
Spellberg
Brad
B
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016883:Diabetic Ketoacidosis / Q000150:complications; D004195:Disease Models, Animal; D004338:Drug Combinations; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009503:Neutropenia / Q000150:complications; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000627:therapeutic use*; D012233:Rhizopus / Q000187:drug effects / Q000472:pathogenicity; D016896:Treatment Outcome; D020096:Zygomycosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality
D000935:Antifungal Agents; D004338:Drug Combinations; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B